Clinical Trial Search

Primary: Percentage of Participants Achieving ≥ 90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 90) at Week 24 — 74.6; 48.1; 68.5; 29.3 percentage of…

Primary: Episodes Per Day — 2.22 Episodes per day

Primary: Correction Rate in Memory Association Recall — .106; .031 units on a scale

Primary: Number of Treatment-Emergent Adverse Events (Safety and Tolerability) — 34; 54; 51; 20 Number of TEAEs

Primary: Proportion of Patients With Neutropenia Compared to Historical Controls — 0; 30 Participants — p=0.02

Primary: Number of Participants With Treatment-Emergent Adverse Events Including SAEs [Safety and Tolerability] of NOX66 Combined With Radiation Therapy at Multiple Timepoints…

Primary: Perception of Immersive Technologies Experience — 24; 19; 7; 3 Number of mentionned items

Primary: Change in Hemoglobin A1c (HbA1c) From Baseline to Twelve Weeks by Study Arm — -0.023; 0.131 Percentage of glycated hemoglobin — p=0.900

Primary: Atrial Fibrillation (AF) Burden Defined as the Mean Amount of Time Spent in AF Over a Pre-specified Period of Time (Excluding Short AF Episodes of ≤30 Seconds) by the…

Primary: Time to "Fitness for Discharge" From the Recovery Room — 165.64; 154.60 Minutes

Primary: Difference in Proportion With Failure (Clinical or Virological) — 0; 3; 0; 0 Participants — p== 0.004

Primary: Therapeutic Equivalence Based on Change From Baseline in ISS7 at Week 12 in 300 mg Groups — -9.25; -9.96 score on a scale

Primary: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) — 6; 0; 0; 0 Participants

Primary: Change in Treatment Seeking Steps — 6.43; 10.08; 7.65; 9.58 score on a scale

Primary: Change is 24-hour Systolic Blood Pressure From Baseline to 4 Weeks — -5.9; -7.5; -8.4 mmHg